Clinical evidence from patients with aggressive clinical phenotypes in cancer patients shows that KRAS mutations lead to poor therapeutic outcomes and overall survival, regardless of cancer stage, emphasizing the need for targeted therapy for KRAS-mutated cancers 5,6. The gene discussed is KRAS; the disease is cancer.